Ensayos clínicos

8.676 ensayos encontrados

ReclutandoFase 3ClinicalTrials.gov

A Randomized, Double-blind, Double-dummy, Placebo-controlled, Multicenter, Phase 3 Study Assessing the Efficacy, Safety, and Tolerability of 2 Doses of Remibrutinib Over a 68-week Treatment Period in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE-2)

INTERVENTIONALInicio: 20 de mar de 2025ID: NCT06840392

ReclutandoFase 3ClinicalTrials.gov

A Randomized, Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan Versus Trastuzumab, Chemotherapy, and Pembrolizumab for the First Line Treatment of HER2-positive Gastric Cancer (ARTEMIDE-Gastric01)

INTERVENTIONALInicio: 1 de mar de 2025ID: NCT06764875

ReclutandoFase 2ClinicalTrials.gov

A Phase 2 Multi-Cohort, Open-Label, Multi-Center Clinical Study Evaluating the Efficacy and Safety of Disitamab Vedotin (RC48-ADC) Alone or in Combination With Pembrolizumab in Subjects With Locally-Advanced Unresectable or Metastatic Urothelial Carcinoma That Expresses HER2

INTERVENTIONALInicio: 3 de may de 2022ID: NCT04879329

ReclutandoFase 2ClinicalTrials.gov

A Phase 2, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Rademikibart as an Add-on Treatment for Acute Exacerbation in Adult and Adolescent Participants With Asthma and Type 2 Inflammation

INTERVENTIONALInicio: 8 de ago de 2025ID: NCT06940141

ReclutandoClinicalTrials.gov

International Prospective REgistry on Pre-pectorAl Breast REconstruction

OBSERVATIONALInicio: 12 de sept de 2023ID: NCT05817175

ReclutandoFase 3ClinicalTrials.gov

A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled Study of Acoramidis for Transthyretin Amyloidosis Prevention in the Young (ACT-EARLY Trial)

INTERVENTIONALInicio: 12 de may de 2025ID: NCT06563895

ReclutandoFase 3ClinicalTrials.gov

A Phase 2/3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Efficacy, Safety and Tolerability of BHV-7000 in Subjects With Refractory Focal Onset Epilepsy

INTERVENTIONALInicio: 14 de mar de 2024ID: NCT06132893

ReclutandoClinicalTrials.gov

Role of Mucosal Impedance Measurement for the Diagnosis of Gastroesophageal Reflux Disease

OBSERVATIONALInicio: 12 de dic de 2024ID: NCT06339801

ReclutandoClinicalTrials.gov

Registry of Deep Brain Stimulation With the VERCISE™ System: Vercise DBS Registry

OBSERVATIONALInicio: 4 de mar de 2014ID: NCT02071134

ReclutandoFase 3ClinicalTrials.gov

A Study to Investigate the Efficacy and Safety of Orforglipron Once Daily in Participants With Peripheral Artery Disease: A Randomized, Double-Blind, Placebo Controlled Trial

INTERVENTIONALInicio: 31 de oct de 2025ID: NCT07223593

ReclutandoFase 2ClinicalTrials.gov

Castration With Abiraterone 250 mg Without LHRH Analogs or Blockers in Patients With Prostate Cancer Requiring Hormonal Intensification (Multicenter Phase 2)

INTERVENTIONALInicio: 1 de dic de 2025ID: NCT07299292

ReclutandoFase 3ClinicalTrials.gov

A Phase III Randomised Clinical Trial Comparing Sentinel Node Biopsy With No Retroperitoneal Node Dissection in Apparent Early-Stage Endometrial Cancer

INTERVENTIONALInicio: 18 de ene de 2021ID: NCT04073706

ReclutandoFase 2ClinicalTrials.gov

A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants With Inadequately Controlled Moderate to Severe Asthma

INTERVENTIONALInicio: 11 de jul de 2023ID: NCT05851443

ReclutandoFase 2ClinicalTrials.gov

An Open-Label Multicenter Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Inebilizumab in Pediatric Subjects With Neuromyelitis Optica Spectrum Disorder

INTERVENTIONALInicio: 3 de jul de 2023ID: NCT05549258

ReclutandoFase 3ClinicalTrials.gov

A Randomized, Placebo-controlled, Double-blind, Multi-center, Phase III Trial to Assess the Efficacy and Safety of Trimodulin (BT588) in Adult Hospitalized Subjects With Severe Community-acquired Pneumonia (sCAP)

INTERVENTIONALInicio: 9 de sept de 2023ID: NCT05722938

ReclutandoFase 3ClinicalTrials.gov

Efficacy and Safety of NNC0487-0111 s.c. Once-weekly in Participants With Obesity (AMAZE 1)

INTERVENTIONALInicio: 24 de feb de 2026ID: NCT07339423

ReclutandoClinicalTrials.gov

Description of the Impact of the Modelo Sentido's® on the Adaptive Behaviors of Children Between 3 and 7 Years Old, on the Autism Spectrum and Other Associated Neurodevelopmental Challenges

OBSERVATIONALInicio: 30 de oct de 2023ID: NCT06477666

ReclutandoFase 3ClinicalTrials.gov

A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Investigate the Efficacy, Safety, and PK/ PD of Finerenone, in Addition to Standard-of-care, in Pediatric Patients, 6 Months to < 18 Years of Age With Heart Failure (HF) and Left Ventricular Systolic Dysfunction (LVSD)

INTERVENTIONALInicio: 19 de nov de 2025ID: NCT07188805

ReclutandoFase 3ClinicalTrials.gov

An Open-label Phase II/III Randomized Trial of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Monotherapy as a First Line Therapy in Patients With Unresectable Recurrent, or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Which is Positive for Human Papilloma Virus 16 (HPV16+) and Expresses PD-L1

INTERVENTIONALInicio: 7 de ene de 2021ID: NCT04534205

ReclutandoFase 3ClinicalTrials.gov

A Randomised, Double-blind, Placebo-controlled, Phase III Study of Adjuvant Saruparib (AZD5305) in Patients With BRCAm Localised High-Risk Prostate Cancer Receiving Radiotherapy With Androgen Deprivation Therapy (EvoPAR-Prostate02).

INTERVENTIONALInicio: 6 de ago de 2025ID: NCT06952803